Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 未分類

第四期肺癌康復奇蹟|鍾喜英HER2基因突變成功治療個案 - 李宇聰醫生解析基因檢測重要性

Stage 4 Lung Cancer Recovery Miracle | A Successful Treatment Case of HER2 Gene Mutation

Ms. Zhong Xiying was diagnosed with multiple metastases of stage 4 lung cancer in the brain, liver and bone, and once wanted to give up treatment. Dr. Li Yu Chung, Jacky insisted on genetic testing to find rare HER2 mutations, and quickly formulated a personalized targeted treatment plan to successfully control the condition. Real cases share how genetic testing has changed destiny, and now Ms. Zhong can travel with her family and enjoy happiness. The United Cancer Centre of Hong Kong provides comprehensive genetic testing and personalized treatment services.

立即閱讀
December 3, 2025 No Comments
李宇聰醫生主講「擁抱希望 - 早期乳癌新認知」講座 | 全球華人乳癌組織聯盟 GCBC × 香港聯合腫瘤中心 HKUOC | 2025年10月31日

Dr. Li Yu Chung, Jacky will present a lecture titled "Embracing Hope – New Understanding of Early Breast Cancer" | Global Chinese Breast Cancer Organization Alliance (GCBC) × HKUOC | October 31, 2025

2025年10月31日(星期五),香港聯合腫瘤中心(HKUOC)臨床腫瘤科李宇聰醫生應邀在全球華人乳癌組織聯盟(GCBC)的患者教育講座中,分享早期乳

立即閱讀
December 2, 2025 No Comments
2025年9月18日 宏利健康講座:肺癌、乳癌及前列腺癌治療新趨勢 - 香港聯合腫瘤中心李宇聰醫生分享

Manulife Health Seminar, September 18, 2025: New Trends in the Treatment of Lung Cancer, Breast Cancer, and Prostate Cancer – Dr. Li Yu-chung of the Hong Kong United Oncology Centre shares his insights.

On September 18, 2025, Dr. Li Yu Chung, Jacky of the Department of Clinical Oncology at the Hong Kong United Oncology Centre (HKUOC) will share the latest treatment trends in lung cancer, breast cancer, and prostate cancer at the Manulife Health Seminar. The seminar will be held at Manulife Tower in Kwun Tong from 10:30 a.m. to 11:30 a.m. All are welcome to attend and learn about the cutting-edge treatment technologies and personalized plans!

立即閱讀
December 1, 2025 No Comments

NCT06966700: Trofuse-032/MK2870-032 Research

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
November 19, 2025 No Comments
Vorasidenib IDH1/2抑制劑分子結構,用於治療IDH突變型星形細胞瘤及少突膠質細胞瘤

The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma

The U.S. FDA approved the IDH1/2 inhibitor Vorasidenib for use in patients with specific astrocytoma and oligodendrocytoma in August 2024. The INDIGO clinical trial has shown that it significantly prolongs the survival period without progress, bringing new treatment options to patients with IDH mutant glioma. Learn about applicable patients, medication recommendations, and safety information.

立即閱讀
September 17, 2025 No Comments
香港聯合腫瘤中心李宇聰醫生講解肺癌治療新趨勢

Sing Tao Front Page Exclusive Interview: 55% of New Lung Cancer Cases Are at Advanced Stages, Personalized Therapy Helps Reduce Recurrence Risk

Sing Tao Headline invited Dr. Li Yu Chung, Jacky to analyze the trend of lung cancer treatment. In 2022, 55% of new lung cancer diseases have reached stage 4, with a survival rate of 72.4% in stage 1 vs. 24.6% in stage 3. The United Cancer Centre of Hong Kong provides personalized lung cancer treatment options guided by genetic testing to help reduce the risk of recurrence, improve treatment effectiveness and early screening success rate.

立即閱讀
August 21, 2025 No Comments

T-DXd therapy for advanced solid tumors with HER2-activating mutations

針對帶有激活HER2突變的晚期實體腫瘤之T-DXd療法 根據Bob T. Li醫學博士、哲學博士、公共衛生碩士及其團隊在《The Lancet Onc

立即閱讀
July 9, 2025 No Comments

NCCN Oncology Clinical Practice Guidelines: Key Points for the 2025 Update, a new pattern of bladder cancer treatment

NCCN腫瘤臨床實踐指南:2025年更新要點 膀胱癌治療新格局 科羅拉多大學癌症中心Thomas W. Flaig博士指出,2025版指南針對BCG無

立即閱讀
July 9, 2025 No Comments

Survival Advantage of Pertuzumab Re-treatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer

HER2陽性局部晚期/轉移性乳癌:帕妥珠單抗再治療的生存優勢 (基於《臨床腫瘤學雜誌》Yamamoto等學者報告之PRECIOUS研究最終分析) 研究

立即閱讀
July 9, 2025 No Comments

FDA approves T-DXd for patients with HER2-low or ultra-low-reactivity metastatic breast cancer who have previously been treated.

FDA批准T-DXd用於經治療HER2低表現/超低表現轉移性乳癌患者 審批重點 美國FDA基於DESTINY-Breast06第三期試驗結果,核准抗體

立即閱讀
July 9, 2025 No Comments
Page1 Page2 Page3 Page4 Page5
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp:5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook